ArticleAntibiotics (Basel, Switzerland)2021
Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance.
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Comparative effectiveness of antimicrobial regimens for pneumonia caused by drug-resistant Acinetobacter baumannii: a network meta-analysis including cefiderocol and inhaled therapies.BMC infectious diseases · 2026Pooled it
- Real-World Evidence: Cefiderocol Therapeutic Drug Monitoring in Critically Ill, Obese Patients withAntibiotics (Basel, Switzerland) · 2026Article
- Cefiderocol for Treatment of Ventriculitis (4MRGNAntibiotics (Basel, Switzerland) · 2026Article
- High rates of cefiderocol plasma target attainment: results of a retrospective cohort study in 31 critically ill ICU patients.Critical care (London, England) · 2024Article
- Cefiderocol pharmacokinetics in critically ill patients undergoing ECMO support.Critical care (London, England) · 2024Article
- Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.Annals of intensive care · 2023Review
- Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.Annals of intensive care · 2023Review
- Ventilator-associated pneumonia (VAP) and pleural empyema caused by multidrug-resistantInfectious medicine · 2023Article
- Cefiderocol Efficacy in a Real-Life Setting: Single-Centre Retrospective Study.Antibiotics (Basel, Switzerland) · 2023Article
- Real-Life Data on the Effectiveness and Safety of Cefiderocol in Severely Infected Patients: A Case Series.Infectious diseases and therapy · 2023Article
- [Clinical experience using cefiderocol].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023Review
- Pharmacokinetic of Cefiderocol in Critically Ill Patients Receiving Renal Replacement Therapy: A Case Series.Antibiotics (Basel, Switzerland) · 2022Article
- Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation.Journal of clinical medicine · 2022Review
- Cefiderocol Protects against Cytokine- and Endotoxin-Induced Disruption of Vascular Endothelial Cell Integrity in an In Vitro Experimental Model.Antibiotics (Basel, Switzerland) · 2022Article
- Human Serum Proteins and Susceptibility ofBiomedicines · 2022Article
- Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence.Frontiers in pharmacology · 2022Review
- Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol.Clinical pharmacokinetics · 2021Review
- Correction: König et al. Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cefiderocol is a new siderophore-cephalosporin for the treatment of multi-drug resistant Gram-negative pathogens. As a reserve agent, it will and should be used primarily in critically ill patients in the upcoming years. Due to the novelty of the substance little data on the pharmacokinetics in critically ill patients with septic shock and renal failure (including continuous renal replacement therapy and cytokine adsorber therapy) is available. We performed therapeutic drug monitoring in a cohort of five patients treated with cefiderocol, to improve the knowledge on pharmacokinetics in this vulnerable patient population. As expected for a cephalosporin with predominantly renal elimination the maintenance dose could be reduced in patients with renal impairment or on continuous renal replacement therapy. The manufacturer's dosing instructions were sufficient to achieve a drug level well above the MIC. However, the addition of a cytokine adsorber might reduce serum levels substantially, so that in this context therapeutic drug monitoring and dose adjustment are recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.